DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Simvastatin - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Anticholesteremic Agents
  • Antilipemic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors

Dosage Forms

  • Tablet (oral)

Brands / Synonyms

Cholestat; Coledis; Colemin; Corolin; Denan; Juvisync; Labistatin; Lipex; Liponorm; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simcor; Simovil; Simvastatin [Usan:Ban:Inn]; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; Sinvacor; Sivastin; Synvinolin; Vasotenal; Vytorin; Zocor; Zocord

Indications

For the treatment of hypercholesterolemia.

Pharmacology

Simvastatin, the methylated form of lovastatin, is an oral antilipemic agent which inhibits HMG-CoA reductase. simvastatin is used in the treatment of primary hypercholesterolemia and is effective in reducing total and LDL-cholesterol as well as plasma triglycerides and apolipoprotein B.

Mechanism of Action

The 6-membered lactone ring of simvastatin is hydrolyzed in vivo to generate mevinolinic acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol.

Absorption

Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues.

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Hepatic, simvastatin is a substrate for CYP3A4.

Contraindications

CONTRAINDICATIONS

Hypersensitivity to any component of this medication.

Active liver disease or unexplained persistent elevations of serum transaminases

Pregnancy and lactation. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during
pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Moreover,
cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development,
including synthesis of steroids and cell membranes. Because of the ability of inhibitors of HMG-CoA reductase such as
ZOCOR to decrease the synthesis of cholesterol and possibly other products of the cholesterol biosynthesis pathway,
ZOCOR is contraindicated during pregnancy and in nursing mothers. ZOCOR should be administered to women of childbearing
age only when such patients are highly unlikely to conceive. If the patient becomes pregnant while taking this drug, ZOCOR
should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus.

Drug Interactions

DRUG INTERACTIONS

CYP3A4 Interactions

Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma
concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing
the elimination of simvastatin.

Itraconazole

Ketoconazole

Erythromycin

Clarithromycin

Telithromycin

HIV protease inhibitors

Nefazodone

Cyclosporine

Large quantities of grapefruit juice (>1 quart daily)

Interactions with lipid-lowering drugs that can cause myopathy when given alone

Myopathy/Rhabdomyolysis.

The risk of myopathy is increased by gemfibrozil and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).

Other drug interactions

Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of
simvastatin

Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil
with higher doses of simvastatin

Propranolol: In healthy male volunteers there was a significant decrease in mean Cmax, but no change in AUC, for simvastatin total
and active inhibitors with concomitant administration of single doses of ZOCOR and propranolol. The clinical relevance of this
finding is unclear. The pharmacokinetics of the enantiomers of propranolol were not affected.

Digoxin: Concomitant administration of a single dose of digoxin in healthy male volunteers receiving simvastatin resulted in a slight
elevation (less than 0.3 ng/mL) in digoxin concentrations in plasma (as measured by a radioimmunoassay) compared to concomitant
administration of placebo and digoxin. Patients taking digoxin should be monitored appropriately when simvastatin is initiated.

Warfarin: In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day
modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR),
increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. With other reductase
inhibitors, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin
anticoagulants concomitantly. In such patients, prothrombin time should be determined before starting simvastatin and frequently
enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has
been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If
the dose of simvastatin is changed or discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated
with bleeding or with changes in prothrombin time in patients not taking anticoagulants.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012